Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
about
Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus.Middle East respiratory syndrome coronavirus: five years later.Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light.MERS-CoV: Understanding the Latest Human Coronavirus Threat.Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infectionCurrent understanding of middle east respiratory syndrome coronavirus infection in human and animal models
P2860
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@en
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@nl
type
label
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@en
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@nl
prefLabel
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@en
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@nl
P2093
P2860
P356
P1433
P1476
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
@en
P2093
Abrar Alghamdi
Anwar M Hashem
Ayman T Abbas
Loai A Siddiq
Mohammad A Sanki
Muhanna K Al-Muhanna
Rowa Y Alhabbab
Sawsan S Al-Amri
Xuguang Li
P2860
P2888
P356
10.1038/SREP44875
P407
P50
P577
2017-03-23T00:00:00Z